Phase II multicenter single-arm study evaluating the safety and efficacy of everolimus as a first-line treatment in newly-diagnosed patients with advanced GI neuroendocrine tumors.

Hellenic Cooperative Oncology Group0 个研究点目标入组 29 人开始时间: 2012年4月18日最近更新: 2019年12月10日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 29

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Male or female, aged =18 years of age.
•2.Newly diagnosed patients with biopsy-proven well or moderately differentiated advanced (metastatic or unrectable) GI or pancreatic neuroendocrine tumor.
•3.Measurable disease based on R?CIST 1.1 using a triphase CT scan or multi-phase MRI scan.
•4.Patients with a ki-67 measurement prior to their enrollment to the study.
•5.Performance status 0-2 on the WHO scale.
•6.Adequate bone marrow function as shown by:ANC = 1.5 x 10^9/L,Platelets = 100 x 10^9/L,Hemoglobin >9 g/dL.
•7.Adequate liver function as shown by:Serum bilirubin = 1.5 x ULN,ALT/SGPT and AST/SGOT = 2.5 x ULN (? = 5 x ULN in patients with known liver metastases),INR < 1.3 (INR < 3 in patients treated with anticoagulants).
•8.Adequate renal function as shown by: serum creatinine = 1.5 x ULN.
•9.Fasting serum cholesterol = 300 mg/dL or = 7.75 mmol/L and fasting triglycerides = 2.5 x ULN. Note: In case one or both the above upper limits are exceeded, patient enrollment can only be performed upon proper antilipidemic treatment initiation.
•10.Women of childbearing potential, with a negative serum or urine pregnancy test within 48 hours prior to first study treatment administration.
•11.Signed informed consent form obtained before any trial related activity, including the screening phase, according to the applicable law and ICH/GCP requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 27
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

排除标准

•1.Patients with poorly differentiated or undifferentiated GI or pancreatic neuroendocrine carcinoma.
•2.Previous or concurrent cytotoxic chemotherapy, immunotherapy or radiotherapy.
•3.Hepatic artery embolization or cryoablation of hepatic metastasis within 1 month of study enrollment.
•4.Prior therapy with mTOR inhibitors (for example sirolimus, temsirolimus, everolimus).
•5.Patients receiving chronic treatment with corticosteroid immunosuppressives.
•6.Uncontrolled diabetes mellitus as defined by fasting serum glucose > 1.5 x ULN.
•7.Patients who have any severe and/or uncontrolled medical conditions such as:
•·unstable angina pectoris, symptomatic congestive heart failure NYHA class II, III, IV, myocardial infarction = 6 months prior to enrollment, serious uncontrolled cardiac arrhythmia (LVEF < 50 %)
•·active or uncontrolled severe infection
•·cirrhosis, chronic active hepatitis, chronic persistent hepatitis or inadequate hepatic function (ALT/SGPT and AST/SGOT > 5 x ULN)
•·inadequate bone marrow (ANC < 1.5 x 10^9/L, platelets < 100 x 10^9/L, hemoglobin = 9 g/dL) or renal failure (serum creatinine > 1.5 x ULN
•·severely impaired lung function (patients needing oxygen support).
•8.Active bleeding diathesis or on oral treatment with vitamin K antagonists (apart from low-dose coumadine).
•9.Performance status =3 on the WHO scale.
•10.Patients with a known history of HIV seropositivity. Screening for HIV infection at baseline is not required.
•11.No other prior or concurrent malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, or treated in situ cancer of the cervix, or any other cancer from which the patient has been disease free for = 3 years.
•12.Patients within 28 days post-major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury to avoid wound healing complications. Minor procedures and percutaneous biopsies or placement of vascular access device require 7 days prior to study entry. Note: Patients must have recovered from the acute effects of surgery prior to enrollment.
•13.Female patients who are pregnant or nursing (lactating).
•14.Adults with reproductive potential who are not using effective birth control methods. If barrier contraceptive measures are being used, these must be continued throughout the study by both sexes.
•15.Patients participating in another clinical trial or receiving an investigational drug.
•16.Patients unwilling or unable to comply with the protocol at the investigator’s discretion.

研究者

发起方

Hellenic Cooperative Oncology Group

相似试验

招募中

2 期

A multicenter single-arm P2 to evaluate safety and efficacy of the total neoadjuvant therapy for cT2 rectal cancer.rectal cancerlocal advanced rectal cancer,radiation therapy,total neoadjuvant therapy,chemotherapy,surgeryRectal Neoplasms

JPRN-jRCTs051230014emura Mamoru45

招募中

1 期

Treatment for breast cancer patients with meninges invaded by tumor cellsPatients having a HER2-amplified metastatic breast cancer with evolutive leptomeningeal metastases (LM) requiring intrathecal therapy

CTIS2022-502351-60-00nicancer30

进行中（未招募）

1 期

A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaCytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104

CTIS2023-507899-47-00Goethe University Frankfurt40

进行中（未招募）

1 期

DALY II USA/MB-CART2019.1 for DLBC

CTIS2023-508508-39-01Miltenyi Biomedicine GmbH110

进行中（未招募）

1 期

A clinical study exploring the effect of osimertinib and radiation therapy, in people with newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Treatment naïve patients with synchronous, oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC with or without T790M resistance mutationMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-004114-35-NLETOP IBCSG Partners Foundation60